Stifel Nicolaus Starts Loxo Oncology (LOXO) at Buy

Go back to Stifel Nicolaus Starts Loxo Oncology (LOXO) at Buy

Cowen Starts Loxo Oncology (LOXO) at Outperform

September 2, 2014 6:54 AM EDT

Cowen initiated coverage on Loxo Oncology (NASDAQ: LOXO) with an Outperform rating.

For an analyst ratings summary and ratings history on Loxo Oncology click here. For more ratings news on Loxo Oncology click here.

Shares of Loxo Oncology closed at $13.01 yesterday.

... More

Oppenheimer Starts Loxo Oncology (LOXO) at Outperform

September 2, 2014 6:28 AM EDT

Oppenheimer initiates coverage on Loxo Oncology (NASDAQ: LOXO) with a Outperform rating and a price target of $20.00.

Analyst Yigal Nochomovitz, Ph.D. commented, "Loxo is an early-stage biotechnology company executing a business plan for targeted cancer drugs that benefits from 1) clear precedent for... More